Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.31%||163.36||0.7%||$1395.05m|
|BMY||Bristol-Myers Squibb Co.||-0.47%||61.76||1.0%||$871.78m|
|MRK||Merck & Co., Inc.||-0.04%||74.55||0.7%||$835.06m|
|LLY||Eli Lilly & Co.||-0.32%||203.04||1.1%||$779.17m|
|VYNE||VYNE Therapeutics, Inc.||-1.90%||7.74||0.0%||$98.29m|
|NVO||Novo Nordisk A/S||0.15%||72.45||0.1%||$93.17m|
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The companyÃ¢â‚¬â„¢s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.